全文获取类型
收费全文 | 4323篇 |
免费 | 345篇 |
国内免费 | 17篇 |
专业分类
耳鼻咽喉 | 37篇 |
儿科学 | 93篇 |
妇产科学 | 163篇 |
基础医学 | 777篇 |
口腔科学 | 61篇 |
临床医学 | 360篇 |
内科学 | 745篇 |
皮肤病学 | 236篇 |
神经病学 | 462篇 |
特种医学 | 164篇 |
外科学 | 798篇 |
综合类 | 40篇 |
一般理论 | 3篇 |
预防医学 | 230篇 |
眼科学 | 131篇 |
药学 | 226篇 |
中国医学 | 1篇 |
肿瘤学 | 158篇 |
出版年
2021年 | 44篇 |
2019年 | 36篇 |
2018年 | 48篇 |
2017年 | 46篇 |
2016年 | 44篇 |
2015年 | 54篇 |
2014年 | 81篇 |
2013年 | 88篇 |
2012年 | 127篇 |
2011年 | 132篇 |
2010年 | 77篇 |
2009年 | 71篇 |
2008年 | 129篇 |
2007年 | 151篇 |
2006年 | 179篇 |
2005年 | 154篇 |
2004年 | 147篇 |
2003年 | 157篇 |
2002年 | 147篇 |
2001年 | 105篇 |
2000年 | 109篇 |
1999年 | 98篇 |
1998年 | 35篇 |
1997年 | 34篇 |
1996年 | 36篇 |
1992年 | 74篇 |
1991年 | 68篇 |
1990年 | 83篇 |
1989年 | 87篇 |
1988年 | 82篇 |
1987年 | 71篇 |
1986年 | 60篇 |
1985年 | 71篇 |
1984年 | 57篇 |
1983年 | 40篇 |
1982年 | 48篇 |
1981年 | 42篇 |
1980年 | 35篇 |
1979年 | 55篇 |
1978年 | 37篇 |
1977年 | 57篇 |
1976年 | 35篇 |
1975年 | 43篇 |
1974年 | 55篇 |
1973年 | 45篇 |
1972年 | 44篇 |
1971年 | 37篇 |
1970年 | 51篇 |
1968年 | 49篇 |
1913年 | 48篇 |
排序方式: 共有4685条查询结果,搜索用时 15 毫秒
1.
Susan E. Hickman Alexia M. Torke Greg A. Sachs Rebecca L. Sudore Anne L. Myers Qing Tang Giorgos Bakoyannis Bernard J. Hammes 《Journal of pain and symptom management》2019,57(6):1143-1150.e5
ContextIt is especially important that patients are well informed when making high-stakes, preference-sensitive decisions like those on the Physician Orders for Life-Sustaining Treatment (POLST) form. However, there is currently no way to easily evaluate whether patients understand key concepts when making these important decisions.ObjectivesTo develop a POLST knowledge survey.MethodsExpert (n = 62) ratings of key POLST facts were used to select items for a POLST knowledge survey. The survey was administered to nursing facility residents (n = 97) and surrogate decision-makers (n = 112). A subset (n = 135) were re-administered the survey after a standardized advance care planning discussion to assess the scale's responsiveness to change.ResultsThe 19-item survey demonstrated adequate reliability (α = 0.72.). Residents' scores (x = 11.4, standard deviation 3.3) were significantly lower than surrogate scores (x = 14.7, standard deviation 2.5) (P < 0.001). Scores for both groups increased significantly after administration of a standardized advance care planning discussion (P < 0.001). Although being a surrogate, age, race, education, cognitive functioning, and health literacy were significantly associated with higher POLST Knowledge Survey scores in univariate analyses, only being a surrogate (P < 0.001) and being white (P = 0.028) remained significantly associated with higher scores in multivariate analyses.ConclusionThe 19-item POLST Knowledge Survey demonstrated adequate reliability and responsiveness to change. Findings suggest the survey could be used to identify knowledge deficits and provide targeted education to ensure adequate understanding of key clinical decisions when completing POLST. 相似文献
2.
Multivariate survival data are frequently encountered in biomedical applications in the form of clustered failures (or recurrent events data). A popular way of analyzing such data is by using shared frailty models, which assume that the proportional hazards assumption holds conditional on an unobserved cluster-specific random effect. Such models are often incorporated in more complicated joint models in survival analysis. If the random effect distribution has finite expectation, then the conditional proportional hazards assumption does not carry over to the marginal models. It has been shown that, for univariate data, this makes it impossible to distinguish between the presence of unobserved heterogeneity (eg, due to missing covariates) and marginal nonproportional hazards. We show that time-dependent covariate effects may falsely appear as evidence in favor of a frailty model also in the case of clustered failures or recurrent events data, when the cluster size or number of recurrent events is small. When true unobserved heterogeneity is present, the presence of nonproportional hazards leads to overestimating the frailty effect. We show that this phenomenon is somewhat mitigated as the cluster size grows. We carry out a simulation study to assess the behavior of test statistics and estimators for frailty models in such contexts. The gamma, inverse Gaussian, and positive stable shared frailty models are contrasted using a novel software implementation for estimating semiparametric shared frailty models. Two main questions are addressed in the contexts of clustered failures and recurrent events: whether covariates with a time-dependent effect may appear as indication of unobserved heterogeneity and whether the additional presence of unobserved heterogeneity can be detected in this case. Finally, the practical implications are illustrated in a real-world data analysis example. 相似文献
3.
Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder 总被引:1,自引:0,他引:1
G E Tesar J F Rosenbaum M H Pollack M W Otto G S Sachs J B Herman L S Cohen S A Spier 《The Journal of clinical psychiatry》1991,52(2):69-76
To test the reported antipanic efficacy of clonazepam, the authors randomized 72 subjects with panic disorder to 6 weeks of treatment with either alprazolam, clonazepam, or placebo. Endpoint analysis demonstrated a significant beneficial effect of both active treatments, but not placebo treatment, on the frequency of panic attacks, overall phobia ratings, and the extent of disability. Comparison of the two active treatments revealed no significant differences and no consistent tendency for one agent to be favored over another, although power to detect small differences was limited. Sedation and ataxia were the most common side effects reported, but these effects were mild and transient and did not interfere with treatment outcome. The results of this double-blind, placebo-controlled trial are consistent with previous reports of clonazepam's antipanic efficacy. 相似文献
4.
Theodor Abelin 《Sozial- und Pr?ventivmedizin》1987,32(6):277-279
Ohne Zusammenfassung 相似文献
5.
Stephan Michael Erdmann Bernhardt Sachs Hans F Merk 《American Journal of Contact Dermatitis》2002,13(1):37-38
Phenylephrine is widely used as an ophthalmic drug. However, there are only very few reports on allergic contact dermatitis induced by phenylephrine. In addition, little is known on cross reactivity patterns between the sympathomimetics phenylephrine, epinephrine and ephedrine which share a similar chemical structure. We report on a man who developed allergic contact dermatitis to Neosynerphin POS eyedrops containing phenylephrine hydrochloride. Cross reactivity between phenylephrine, epinephrine and ephedrine was studied by patch testing. Patch tests were performed with the European standard, an ophthalmics and preservatives series, Neosynerphin POS eyedrops, phenylephrine hydrochloride 10% aq., epinephrine and ephedrine (both 1.0 % aq.). Test sites were read after 48, 72 and 168 hours according to the recommendations of the ICDRG. Neosynerphin POS and phenylephrine hydrochloride 10 % aq. gave positive reactions, whereas epinephrine and ephedrine tested negative. Although phenylephrine is an epinephrine analog delayed type hypersensitivity to phenylephrine did not result in cross reactivity with chemically related epinephrine and ephedrine. 相似文献
6.
A 59-year-old hypertensive male, 1 year after uncomplicatedmitral annuloplasty for regurgitation with MAZE procedure, witha history of chronic obstructive pulmonary disease and repeatedpulmonary 相似文献
7.
Bernd Huber Ines Hauser Verena Horstmann Gabi Jokeit Sylvia Liem Theodor May Thomas Meinert Enrique Robertson Heide Schorlemmer Wolfgang Wagner Michael Seidel 《Seizure》2007,16(1):35-42
This study was designed to describe the course of epilepsy (in terms of seizure frequency) and to assess the variables (antiepileptic therapy regimens and others) correlated to improvement. Seizure frequency (categories: seizure free, more than one seizure/year, monthly seizures, weekly seizures and daily seizures) and antiepileptic medication were retrospectively compared between 1992 and 2002 in a large cohort of 550 inpatients with chronic epilepsy and different degrees of intellectual disability or multiple handicaps. RESULTS: Seizure frequency decreased significantly (p<0.001). 218 of the 394 patients (55.3%) not seizure free in 1992 improved (changed into a better frequency category). The improvement rate was marginally higher in patients who had undergone a medication change (p=0.08). A high seizure frequency in 1992 (p=0.016) and older age (p=0.006), but not epilepsy syndrome or degree of intellectual disability, were predictors for improvement (stepwise logistic regression analysis). 56.4% of the improved patients were on combinations of two AEDs (17.4%, monotherapy; 20.2%, triple therapy). The most frequent therapy regimens in the improved patients were lamotrigine/valproate (48 patients), carbamazepine/phenobarbital (21) and carbamazepine only (19). Lamotrigine/valproate was effective in all kinds of epileptic syndromes. Most patients on lamotrigine had serum concentrations above 10microg/ml, approximately one half had dosages above 200mg/day. The rate of seizure freedom increased from 28.4 to 37.6%. The 84% of the patients seizure free in 1992 remained seizure free. Predictors for seizure freedom in 2002 were higher age (stepwise logistic regression, p<0.0005) and seizure freedom in 1992 (p<0.0005). CONCLUSIONS: Substantial improvement can be achieved even in intellectually disabled patients with chronic epilepsy. Although the rate of seizure freedom is reduced in comparison with a non-ID population, once seizure freedom has been achieved it is most likely to continue. For a majority of this patient population, monotherapy may not be sufficient. Lamotrigine/valproate appears to be a major therapeutic innovation. 相似文献
8.
Practical management of patients with non-small-cell lung cancer treated with gefitinib. 总被引:7,自引:0,他引:7
Neelam T Shah Mark G Kris William Pao Leslie B Tyson Barbara M Pizzo Murk-Hein Heinemann Leah Ben-Porat Dana L Sachs Robert T Heelan Vincent A Miller 《Journal of clinical oncology》2005,23(1):165-174
PURPOSE: The use of gefitinib, the first drug approved to inhibit the epidermal growth factor receptor tyrosine kinase, is indicated in patients with non-small-cell lung cancer with tumors progressive after chemotherapy. The unique mechanism of action of this agent leads to distinctive patterns of response and toxicity in persons with lung cancer. Many of the principles of management relevant to gefitinib are distinct from those with conventional cytotoxic drugs. To meet this need, we present practical guidelines on the use of gefitinib in patients with non-small-cell lung cancer. METHODS: This article reviews gefitinib's indications, dosing, response phenomena, and patterns of relapse in individuals with radiographic response. RESULTS: We present our recommendations for the management of rash and diarrhea caused by this agent. CONCLUSION: This information can guide practitioners and help them inform their patients about what to expect when they receive gefitinib. 相似文献
9.
10.